One previous study demonstrated that SETD2 (HM gene) was associated with lower survival in TMZ-treated GBM patients with methylated MGMT promoters, and played a role in MSH6-mediated TMZ resistance.12 However, the same study targeted multiple histone demethylases resulting in restored TMZ sensitivity in SETD2-mut cell lines. This evidence concerns the gene MGMT and glioblastoma.